Physician profile
Scott Martin
NPI 1437388055
$6,930.29
in general payments reported to CMS, 2019-2025
27 companies · $33.44 in 2025
The $33.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,247 · 2020: $2,057 · 2021: $1,896 · 2022: $625 · 2023: $58.05 · 2024: $13.68 · 2025: $33.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $980.42 | 2019-2022 | |
| Novo Nordisk INC | $951.27 | 2019-2022 | |
| Lilly USA, LLC | $586.71 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $465.14 | 2019-2022 | |
| Smith+Nephew, INC. | $456.48 | 2019-2024 | Collagenase Santyl |
| Pfizer INC. | $416.83 | 2019-2022 | |
| Amgen INC. | $396.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $345.26 | 2019-2021 | |
| Astellas Pharma US INC | $336.55 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $291.01 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.03 | 2019-2022 | |
| Organogenesis INC. | $181.17 | 2019-2021 | |
| Abbott Laboratories | $161.91 | 2021-2022 | |
| Abbvie INC. | $152.38 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $117.46 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $88.68 | 2019-2022 | |
| Amarin Pharma, INC. | $82.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $49.90 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $46.74 | 2019-2021 | |
| Eisai INC. | $25.00 | 2020-2021 | |
| Medline Industries LP | $23.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $19.07 | 2021 | |
| Optinose US, INC. | $16.94 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.56 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.